GlassScriptPhysician profile
Alaina Vincent
NPI 1689967747
$6,978.77
in general payments reported to CMS, 2019-2025
28 companies · $4,125 in 2025
The $4,125 reported for 2025 was more than what 98% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $313 · 2022: $643 · 2023: $586 · 2024: $1,312 · 2025: $4,125.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,561 · Consulting Fee: $1,904 · Travel and Lodging: $479 · Education: $78.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,560.85 |
| Consulting Fee | $1,904.00 |
| Travel and Lodging | $479.37 |
| Education | $78.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $2,243.98 | 2021-2025 | |
| Janssen Biotech, INC. | $1,819.61 | 2021-2025 | Erleada, Akeega |
| Astellas Pharma US INC | $504.68 | 2021-2025 | Xtandi |
| Pfizer INC. | $359.74 | 2023-2025 | |
| Teleflex LLC | $271.41 | 2021-2025 | Urolift, Barrigel |
| Janssen Scientific Affairs, LLC | $264.73 | 2022-2024 | Erleada |
| Merck Sharp & Dohme LLC | $251.10 | 2022-2025 | Keytruda, Lynparza, Welireg |
| Astrazeneca Pharmaceuticals LP | $200.53 | 2022-2025 | Lynparza |
| Tolmar, INC. | $189.53 | 2023-2025 | Jatenzo, Eligard |
| Novartis Pharmaceuticals Corporation | $148.71 | 2024-2025 | |
| Boston Scientific Corporation | $111.86 | 2022-2024 | Rezum Generator, Ams 700 |
| Ethicon US, LLC | $79.53 | 2023 | Echelon; Endopath, Vistaseal, Stratafix |
| Abbvie INC. | $69.34 | 2021-2025 | |
| Sumitomo Pharma America, INC. | $63.72 | 2023-2025 | Orgovyx, Gemtesa |
| Myovant Sciences INC. | $49.67 | 2021-2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dendreon Pharmaceuticals LLC | $44.14 | 2024-2025 | Provenge |
| Progenics Pharmaceuticals, INC. | $41.15 | 2024-2025 | |
| Myriad Genetic Laboratories, INC. | $39.44 | 2021-2022 | |
| Procept Biorobotics Corporation | $36.39 | 2024-2025 | Aquabeam System |
| Ambu INC. | $34.74 | 2024 | |
| Axonics, INC. | $29.61 | 2023 | Axonics |
| Smith+Nephew, INC. | $24.78 | 2024 | Collagenase Santyl |
| Immunitybio, INC. | $21.57 | 2025 | |
| Medtronic, INC. | $17.64 | 2024 | Interstim |
| Blue Earth Diagnostics | $17.58 | 2021 | |
| Baxter Healthcare | $16.23 | 2021 | |
| Telix Pharmaceuticals | $13.87 | 2024 | Illuccix |
| Dentsply Ih Ab | $13.49 | 2023 | Lofric |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alaina Vincent listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.